Shares of Helix BioPharma Corp. (TSE:HBP – Get Free Report) passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$1.47 and traded as high as C$1.48. Helix BioPharma shares last traded at C$1.48, with a volume of 416 shares changing hands.
Helix BioPharma Stock Performance
The company has a current ratio of 0.45, a quick ratio of 1.03 and a debt-to-equity ratio of 2.44. The stock has a fifty day moving average price of C$1.47 and a 200-day moving average price of C$1.74. The firm has a market capitalization of C$113.04 million, a price-to-earnings ratio of -37.00 and a beta of 0.43.
Helix BioPharma (TSE:HBP – Get Free Report) last announced its quarterly earnings results on Friday, June 12th. The biopharmaceutical company reported C($0.01) EPS for the quarter. As a group, analysts anticipate that Helix BioPharma Corp. will post -0.11 earnings per share for the current fiscal year.
Helix BioPharma Company Profile
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.
Further Reading
- Five stocks we like better than Helix BioPharma
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
